I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Prostate cancer is one of the most common cancers in males. The incidence and prevalence remain number one in the ranking of male malignancies worldwide. Apart from surgical intervention, external beam radiation therapy (EBRT) is also one of the primary treatment modalities for localized prostate cancer. Several randomized and nonrandomized studies have shown an improvement of tumor local control with the use of higher dose levels when treating prostate cancers \[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6]\].

Over the years, many studies had reported that intensity-modulated radiation therapy (IMRT) possesses a greater dosimetric advantage in dose conformity while comparing to conventional EBRT treatment such as three-dimensional conformal radiation therapy (3D-CRT) \[[@ref7][@ref8]\]. This improvement of dose conformity in treatment planning allowing more sparing for organs at risk (OARs). The avoidance of excessive radiation dose to normal tissues or organs not only yields less treatment-related toxicities \[[@ref9]\] but also provides possibilities for further dose escalation. Clinical treatment outcomes may improve with IMRT \[[@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16]\] and dose escalation due to better tumor control capability. Volumetric-modulated arc therapy or the so-called RapidArc is the latest development in radiation therapy (RT). VMAT allows the RT to be delivered more efficient by utilizing more beam angles hence making reductions in treatment time comparing to IMRT. Studies have also shown that VMAT enables treatment-related side effects to be kept at a reasonable minimum extent \[[@ref17]\].

Here, we tried to report the preliminary results of clinical outcomes, treatment-related toxicities, and prostate-specific antigen (PSA) control in patients treated with high-dose (81 Gy) volumetric-modulated arc therapy for localized prostate cancer at our hospital as a single institution\'s experience.

M[ATERIALS AND METHODS]{.smallcaps} {#sec1-2}
===================================

Between March 2010 and October 2018, 53 patients with clinically localized prostate cancer were treated with definitive RT at our institution. The median follow-up time for the cohort was 46.5 months (range: 4.7--81.0 months). The median age for this patient cohort was 76 years (range: 56--93 years). Pretreatment diagnostic evaluations include pelvic magnetic resonance imaging, chest X-ray, digital rectal examination, serum PSA concentration, bone scan, transrectal ultrasonography, prostate biopsy, and blood profile. All patients had a histologic diagnosis of prostate adenocarcinoma confirmed by a pathologist at our institution. Patients were stratified by prognostic risk group based on the National Comprehensive Cancer Network (NCCN) risk classification criteria (<http://www.nccn.org>).

All patients were treated with Varian\'s RapidArc. Patients were simulated in the supine position. A computed tomography scan was obtained at the time of simulation and images were then transferred to the treatment planning system. Our planning system uses Eclipse anisotropic analytical dose algorithm. The radiation dose delivery uses Varian Trilogy linear accelerator. Treatments were planned with an inverse planning approach with progressive resolution optimizer. All patients received one full arc from 185° to 175° clockwise, and two partial arcs from 90°--185° to 185°--0° counterclockwise. Once the intensity profiles of the VMAT beams were determined, leaf motion files were created, and dose distributions were generated. The treatment was delivered with 10-MV photons in daily fractions of 1.8 Gy. Patient\'s positions were verified with daily on-board-image, and weekly cone-beam computed tomography. The total RT dose of 81Gy was prescribed to the high-risk region and 45 Gy to the subclinical regional lymphatic drainage area. A clinical target volume includes prostate gland, seminal vesicles, and pelvic regional lymph nodes. Pelvic regional lymph nodes were contoured for patients who have =15% of pelvic lymph node risk, which was calculated by Roach\'s formula \[[@ref18]\]. A planning target volume (PTV) was contoured with a 0.7 cm margin in all directions except posterior margin at the prostate-rectal interface, where the margin was reduced to 0.5 cm. The bowels, rectum, bilateral femoral heads, and bladder were contoured as critical normal organ structures. Patients should evacuate bladders before their treatments. Dose constraints were placed on the following normal organ structures: bowels, rectum, bladder, bilateral femoral heads, and PTV. Maximum point dose was limited to 53 Gy for the small bowel, 60 Gy for the large bowel, 68 Gy for the bilateral femoral heads, =103.5% of total volume for the rectal wall, and =107% of total volume for the bladder wall. We limited no more than 30% of the rectal wall to 75.6 Gy (V75.6 =30%) and no more than 53% of the bladder wall to 47 Gy (V47 =53%). The dose distributions were normalized such that the maximum dose to the PTV did not exceed 110% of the prescribed dose.

Acute gastrointestinal (GI), genitourinary (GU), and skin toxicities were scored by RT Oncology Group Acute Radiation Morbidity Scoring Criteria ([http://www.rtog. org/researchassociates/adverseeventreporting/acuteradiationm orbidityscoringcriteria.aspx](http://www.rtog.org/researchassociates/adverseeventreporting/acuteradiationmorbidityscoringcriteria.aspx)). Late GI and GU toxicities were scored by RTOG/EORTC Late Radiation Morbidity Scoring Schema (<http://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiationMorbidityScoringSchema.aspx>). Acute toxicities were defined as beginning from the start of treatment and lasting until 3 months\' post-RT. Late toxicities were defined as occurring after 3 months\' post-RT. Late toxicity was scored according to the RTOG morbidity grading scale.

The database was closed for analysis in October 2018. All endpoints were calculated from the date of radiation treatment completion. Biochemical failure was defined using the 2005 RTOG-ASTRO Phoenix Consensus definition of the nadir PSA concentration plus 2 ng/mL \[[@ref19][@ref20][@ref21]\]. The cause of death was recorded for all patients who died during the analysis. If death was secondary to prostate cancer with clear evidence or the patient had metastatic disease with elevation of PSA at the time of death, then it is denoted as prostate cancer-specific death, or it will be referred to as sensor.

Androgen deprivation therapy (ADT) was prescribed at the discretion of the treating physician and/or the conclusion of tumor board conference. In general, a 6-month course of ADT (3 months\' neoadjuvant + 3 months\' concurrent) was given to patients in intermediate-risk groups. A 6-month--2-year ADT course was given to patients in high or greater risk groups. Six patients in the entire cohort study did not show any records of ever receiving ADT at any time. With majority (47 patients; 88.6%) of the patients received ADT, most of them received ADT for more than 6 months. Patients lost follow-up were censored at the time of their last follow-up observation. Biochemical relapse-free survival rates were defined as surviving without biochemical relapse and calculated using actuarial analyses. Those people whose death was not related to cancer would count as censored. Biochemical relapse-free survival curves were assessed using the Kaplan--Meier method. Predictors of treatment outcome examined by univariate and multivariate analyses with the Cox proportional hazards regression model. Statistical significance was achieved when *P* \< 0.05. We used Rstudio 1.1.463 for all statistics.

The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of the institute. Written informed consent was obtained from all patients before their enrollment in this study. The protocol is approved by the Research Ethics Committee of Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation on October 31, 2018. The committee is under, and operates in accordance with, the Good Clinical Practice Guidelines and government laws and regulations (REC No. IRB 107-216-B).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Fifty-three patients with clinically localized prostate cancer between March 2010 and October 2018 were treated with definitive RT at our institution \[[Table 1](#T1){ref-type="table"}\]. Majority (51 patients; 96.2%) of the patients in this cohort were older than the age of 60 years when diagnosed of prostate cancer. Thirteen and sixteen patients have T stage 2b-2c and tumor T stage =3a, respectively, whereas 24 (45.3%) patients have tumor T stage =2a. For Gleason Score classification, 32 (60.3%) patients have scores below 7, and 12 (22.6%) patients have scores above 7. More than half (52.8%) of the patients had pretreatment PSA over 20 ng/mL. Five (9.4%) patients, 9 (16.9%) patients, and 39 (73.5%) patients belong to low-, intermediate-, and high-risk group according to the NCCN classification, respectively. With the majority (47 patients; 88.6%) of the patients received ADT, most (43 patients; 81.1%) of them received ADT for more than 6 months.

###### 

Patient characteristics

  Patient characteristics        *n* (%)
  ------------------------------ -----------
  Age (y/o) (year)               
   Median                        75
   Range                         56-93
  T stage                        
   ≤T2a                          22 (47.8)
   T2b-T2c                       12 (26.1)
   ≥T3a                          12 (26.1)
  Gleason score                  
   ≤6                            30 (65.2)
   7                             5 (10.9)
   ≥8                            11 (23.9)
  Pretreatment PSA (ng/mL)       
   \<10                          11 (23.9)
   10-20                         25 (54.3)
   \>20                          10 (21.8)
  Risk group                     
   Low                           6 (13)
   Intermediate                  5 (10.9)
   High                          35 (76.1)
  Androgen deprivation therapy   
   Yes                           38 (82.6)
   No                            8 (17.4)

PSA: Prostate-specific antigen

Overall survival/cancer-specific survival {#sec2-1}
-----------------------------------------

A total of 13 patients passed away during this retrospective study. Prostate cancer-related deaths were noted on four patients, one of them belongs to intermediate risk, and the rest belong to high. The 3- and 5-year overall survival rates for all patients are 83% and 68%, respectively \[[Figure 1](#F1){ref-type="fig"}\]. The 3- and 5-year cancer-specific survival rates for all patients are 97.7% and 90.7%, respectively \[[Figure 2](#F2){ref-type="fig"}\].

![Overall survival according to low-, intermediate-, and high-risk prostate cancer. Univariate analysis showed a significant difference (*P* = 0.03), while multivariate analysis did not](TCMJ-32-75-g001){#F1}

![Cancer-specific survival according to low-, intermediate-, and high-risk prostate cancer. Univariate analysis showed no significant difference](TCMJ-32-75-g002){#F2}

Biochemical failure-free survival {#sec2-2}
---------------------------------

The 3-year biochemical failure-free survival according to the 2005 RTOG-ASTRO Phoenix consensus definition of the nadir PSA concentration plus 2 ng/mL was 100%, 87.5% and 84% for the low-, intermediate-, and high-risk groups, respectively \[[Figure 3](#F3){ref-type="fig"}\].

![Biochemical failure-free survival according to low-, intermediate-, and high-risk prostate cancer. Univariate analysis showed no significant difference](TCMJ-32-75-g003){#F3}

Acute and late toxicity {#sec2-3}
-----------------------

The acute side effects of radiotherapy in this cohort were well tolerated. Acute grade I GU toxicity occurred in 10 (18.8%) patients, whereas 4 (7.5%) patients experienced Grade II GU toxicity. There were no patients experienced Grade III or higher acute GU side effects. Acute Grade I and Grade II GI toxicities were noted in 11 (20.7%) and 3 (5.6%) patients, respectively. No patient suffered from acute GI toxicity more severe than Grade II. Grade I skin toxicity occurred in 3 (5.6%) patients, whereas no patient experienced Grade II or higher skin toxicity \[[Table 2](#T2){ref-type="table"}\].

###### 

Toxicity by grade according to skin, genitourinary, and gastrointestinal

                   Grade 0 (%)   Grade I (%)   Grade II (%)   Grade III (%)   Grade IV (%)   Grade V (%)
  ---------------- ------------- ------------- -------------- --------------- -------------- -------------
  Acute toxicity                                                                             
   Skin            50 (94.3)     3 (5.6)       0 (0)          0 (0)           0 (0)          0 (0)
   GU              39 (73.5)     10 (18.8)     4 (7.5)        0 (0)           0 (0)          0 (0)
   GI              39 (73.5)     11 (20.7)     3 (5.6)        0 (0)           0 (0)          0 (0)
  Late toxicity                                                                              
   Skin            53 (100)      0 (0)         0 (0)          0 (0)           0 (0)          0 (0)
   GU              41 (77.3)     6 (11.3)      6 (11.3)       0 (0)           0 (0)          0 (0)
   GI              46 (86.7)     6 (11.3)      1 (1.8)        0 (0)           0 (0)          0 (0)

GU: Genitourinary, GI: Gastrointestinal

According to late toxicity, the result was also acceptable. Forty-one (77.3%) and 46 (86.7%) patients experienced no late GI or GU toxicity, respectively. Grade I late GI toxicity was identified in 6 (11.3%) patients, and 1 patient had Grade II late GI toxicity. No patients experienced GI side effects beyond Grade II. Six (11.3%) patients with Grade I late GU toxicity were noted, and another 6 (11.3%) patients experienced Grade II late GU toxicity. One of the patients with Grade II late GU toxicity had intermittent macroscopic hematuria, where others had experienced only moderate frequency. The volume of the bladder wall to receive a dose of 47 Gy for this patient was 59.3%, and the maximum point dose of total volume for the rectal wall was 107.7%, which were both beyond the dose constraint from our institute. There was no late GU toxicity beyond Grade II \[[Table 2](#T2){ref-type="table"}\]. Intermittent macroscopic hematuria usually resolved after medication or sometimes relieved spontaneously.

Univariate and multivariate analyses showed no factors statistically significant for overall survival, cancer-specific survival, and biochemical failure-free survival. The hazard ratio for intermediate risk to low risk is 0.44, and for high risk to low risk is 0.11, though *P* value showed no statistically significant \[[Table 3](#T3){ref-type="table"}\].

###### 

Univariate and multivariate analysis for overall survival

  Variable              Univariate analysis   Multivariate analysis           
  --------------------- --------------------- ----------------------- ------- ------
  Risk                                                                        
   Low                  1.00                  0.03                            0.1
   Intermediate         0.71                                          0.44    
   High                 0.21                                          0.119   
  Age (years-old)                                                             
   \<80                 1.00                  0.2                     1.00    0.28
   ≥80                  2.17                                          1.92    
  Gleason score                                                               
   ≤7                   1.00                  0.8                             \-
   \>7                  1.19                                                  
  Stage group                                                                 
   Stage I-IIB          1.00                  0.2                     1.00    0.69
   Stage III-IV         0.28                                          1.28    
  Biochemical failure                                                         
   Yes                  1.00                  0.6                             \-
   No                   1.36                                                  

OR: Odds ratio

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This study is the first time in Taiwan to evaluate the feasibility of dose escalation using VMAT with image-guided RT (IGRT) for localized prostate cancer. This report represents the preliminary result of our experience over the past years. There are a few of institutions in Taiwan utilizing definitive RT to treat prostate cancers for a total dose beyond 80 grays. Our data showed that dose escalation to a level of 81 Gy with VMAT and IGRT for localized prostate cancer is well-tolerated with acceptable treatment-related toxicities.

By choosing more conformal techniques, a higher dose of radiation may be feasible for treating prostate cancer. In a prospective dose escalation trial conducted by the RTOG using 3D-CRT (RTOG 9406), the incidence of late toxicity was significantly lower than expected based on controls with conventional 2D techniques. IMRT employ variable intensity across multiple radiation beams leading to the construction of highly conformal dose distributions. This technique is achieved by further dividing each radiation beam into smaller radiation beamlets and varying the individual intensities of these beamlets. IMRT also can produce inhomogeneous dose distributions, which allows the simultaneous delivery of different doses per fraction to separate areas within the target volume. IMRT could facilitate localized dose escalation strategies without increasing total treatment time, which may have the potential radiobiological benefit of reducing the impact of accelerated repopulation in tumor clonogen \[[@ref22][@ref23]\]. One of the most common tumor sites treated with IMRT worldwide is prostate cancer. The use of IMRT allows dose escalation, which has been shown to improve clinical outcomes while simultaneously reducing toxicity by improved OAR sparing \[[@ref1][@ref8][@ref11][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30]\].

More recently, there has been increasing interests in a novel radiation technique called arc-based or rotational therapies in the attempt to overcome some of the limitations associated with fixed-field IMRT. The basic concept of arc therapy is the delivery of radiation from a continuous rotation of the radiation source and allows the patient to be treated from full 360° beam angles. Arc therapy such as VMAT can achieve highly conformal dose distributions with improved target volume coverage and more sparing of nearby normal organs and/or tissues comparing to conventional radiotherapy techniques (3D-CRT or IMRT). VMAT also has the potential to offer additional advantages including greatly reduced treatment delivery time when comparing with conventional static field radiotherapy such as IMRT, thus serves as an alternative form to IMRT. IGRT involves the incorporation of image-checking before and/or during treatment to enable more precise position verification and to allow improvement for the treatment target accuracy. Since VMAT can shorten the treatment delivery time substantially, employing IGRT techniques has become more feasible during daily busy clinical settings.

Shiraishi *et al*. had reported preliminary data regarding their experience in using VMAT for the treatment of localized prostate cancer at the University of Tokyo Hospital in Japan \[[@ref29]\]. In their study, they divided patients into two-dose groups (=72 Gy and 76 Gy). Their results showed 2 (1%) patients developed acute Grade II or higher GI toxicity. Thirty-nine (19%) patients developed acute Grade II GU symptoms. Six (3%) patients developed late Grade II GI toxicity such as rectal bleeding. Two (1%) patients experienced Grade III GI toxicity requiring either one or more blood transfusions or a laser cauterization procedure. No Grade IV or higher GI complications have been observed. Twenty (10%) patients experienced late Grade II GU toxicity, and no one developed Grade III GU toxicity. The 5-year actuarial PSA relapse-free survival rate for low-, intermediate-, and high-risk group was 100%, 91.8%, and 85.3%, respectively \[[Table 4](#T4){ref-type="table"}\].

###### 

The treatment outcome and toxicities comparing with previous study

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Free from failure/biochemical-free survival (%)   Overall survival (%)   Toxicity (Grade II or greater) (%)
  --------------------------------------------- ------------------------------------------------- ---------------------- ------------------------------------
  Thames *et al*. (2003) 78 Gy \[[@ref20]\]     5-year 78                                         5-year 78              GI 26\
                                                                                                                         GU 13

  Peeters *et al*. (2006) 78 Gy \[[@ref3]\]     5-year 66                                         5-year 83              GI 32\
                                                                                                                         GU 39

  Pollack *et al*. (2004) 78 Gy \[[@ref30]\]    5-year 79                                         5-year 91              \-

  Zelefsky *et al* (2008) 81 Gy \[[@ref36]\]    5-year 66                                         7-year 84              \-

  Shiraishi *et al* (2014) 76 Gy \[[@ref29]\]    5-year\                                          \-                     GI 4\
                                                 Low 100\                                                                GU 10
                                                Intermediate 91.8\                                                       
                                                 High 85.3                                                               

  Huang *et al*. 81 Gy                           3-year\                                          3-year 83\             GI 1.8\
                                                 Low 100\                                         5-year 68              GU 11.3
                                                Intermediate 87.5\                                                       
                                                 High 84                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

GU: Genitourinary, GI: Gastrointestinal

In our preliminary report, most patients treated at our institution belonged to high-risk group with a total of 73.5% belonged to this group. The 3- and 5-year overall survival rate for our entire cohort was 83% and 62%, respectively. The 3-year actuarial PSA relapse-free survival rate for low-, intermediate-, and high-risk group was 100%, 87.5%, and 84%, respectively.

It has been reported that excellent long-term PSA control could be achieved when using the dose between 78 and 81 Gy. The average 5-year actuarial PSA relapse-free survival rates according to the nadir plus 2 ng/mL definition were around 100%, 87.5%, and 76.5% for the low-, intermediate-, and high-risk groups, respectively. Initial studies had suggested that higher doses were only being advantageous for intermediate- and high-risk patients \[[@ref4]\]. However, some investigators have shown that low-risk patients may also be beneficial from dose escalation \[[@ref2][@ref6][@ref30][@ref31][@ref32][@ref33][@ref34]\]. Our report shows excellent PSA control across all the risk groups.

Eade *et al*. have actively advocated for the use of doses exceeded 80 Gy for localized prostate cancer \[[@ref35]\]. They believed that when total doses exceeded 80 Gy could result in better local control and ultimately lead to less chance of distant failures than those who received below 80 Gy. In their report, an additional Gy in this dose range could decrease the risk of PSA relapse by 2.2%. Cahlon *et al*. reported that most patients could benefit from treatment when doses were at least 80 Gy and that the plateau on the dose-response curve for prostate cancer lies well above 80 Gy \[[@ref16]\].

As a retrospective study, we acknowledged that there may have some selection biases. Patients with a poorer general condition or higher risk of developing comorbidities may have been advised to receive other treatment modalities or may have been treated to a more conventional dose range. Furthermore, toxicity was evaluated by an individual physician\'s discretion, which has some inherent limitations. Longer follow-up period will be needed to determine the durability of tumor control and the full extent of late effects in this cohort of patients. Only by conducting a randomized trial for such a dose range may be able to determine the real possible benefit of dose escalation for localized prostate cancer patients.

Conclusions {#sec1-5}
===========

With VMAT technique and IGRT, dose escalation for prostate cancer treatment not only can maintain its advantage of treatment outcome but also can increase patients\' quality of life during treatment. The VMAT and IGRT techniques should become a trend for dose-escalating treatment in prostate cancer, while further outcome should be confirmed in randomized control trial.
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